Plenary Session

[PL-4] Somatic mutations at remission serve as a minimal residual disease marker in acute myeloid leukemia

Kiyomi Morita^1,2, Hagop Kantarjian², Feng Wang³, Yuanqing Yan⁴, Carlos Bueso-Ramos⁵, Koji Sasaki², Ghayas Issa², Sa Wang⁵, Jeffrey Jorgensen⁵, Xingzhi Song³, Jianhua Zhang^3,6, Samantha Tippen³, Rebecca Thornton³, Marcus Coyle³, Latasha Little³, Curtis Gumbs³, Naveen Pemmaraju², Naval Daver², Courtney Dinardo², Marina Konopleva², Michael Andreeff², Farhad Ravandi², Jorge Cortes², Tapan Kadia², Elias Jabbour², Guillermo Garcia-Manero², Keyur Patel⁵, P Andrew Futreal³, Koichi Takahashi^2,3,7 (1.Dept. of Hematology and Oncology, The University of Tokyo, 2.Dept. of Leukemia, MD Anderson Cancer Center, 3.Dept. of Genomic Medicine, MD Anderson Cancer Center, 4.Dept. of Biostatistics, MD Anderson Cancer Center, 5.Dept. of Hematopathology, MD Anderson Cancer Center, 6.Institute of Applied Cancer Science, MD Anderson Cancer Center, 7.Dept. of Hematology and Oncology, Kyoto University)